相关实验视频

Updated: Jul 27, 2025

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

在患有节点阳性乳腺癌的患者中,腹逆映射节点的参与

Masakuni Noguchi¹, Masafumi Inokuchi¹, Miki Yokoi-Noguchi¹

¹Department of Breast and Endocrine Surgery, Breast Center, Kanazawa Medical University Hospital, Uchinada, Ishikawa, Japan.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|June 11, 2023

概括

轴心逆映射 (ARM) 节点可以参与乳腺癌患者,即使在哨兵淋巴结活检后. 这些ARM节点应该被移除,特别是在新辅助化疗和临床病理学节点阳性组中,以确保瘤安全.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
淋巴 edem 研究研究淋巴 edem 研究

背景情况:

轴心逆向映射 (ARM) 有助于减少淋巴水,但面临瘤安全问题.
有限的数据存在于ARM节点参与节点阳性乳腺癌患者.

研究的目的:

通过评估ARM节点参与的节点阳性乳腺癌患者来评估ARM手术的瘤安全性.

主要方法:

一项对223名结节阳性乳腺癌患者的研究,这些患者用光ARM进行了下淋巴结解剖.
患者被分为SLN阳性,CpN阳性和NAC组.

主要成果:

在36%的SLN阳性患者中,ARM节点参与其中.
12.2%的SLN阳性患者在活检后有剩余的ARM节点参与.
与CpN阳性组 (64.7%) 相比,NAC组的ARM节点参与率明显较低 (35.4%).

结论:

在节点阳性乳腺癌患者中,ARM节点可能参与其中.
在ARM结节中转移的风险很大,需要在NAC和CPN阳性组中去除它们.
在节点阳性乳腺癌管理中,ARM程序需要仔细考虑瘤安全性.

关键词:

轴心淋巴结解剖的方法轴心的反向映射轴心的反向映射乳腺癌是什么? 乳腺癌是什么哨兵淋巴结活组织检查

更多相关视频

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

相关概念视频